260 related articles for article (PubMed ID: 30709700)
1. The genetics and epigenetics of Neonatal Abstinence Syndrome.
Wachman EM; Farrer LA
Semin Fetal Neonatal Med; 2019 Apr; 24(2):105-110. PubMed ID: 30709700
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic variation in OPRM1 gene in opioid-exposed mother-infant dyads.
Wachman EM; Hayes MJ; Shrestha H; Nikita FNU; Nolin A; Hoyo L; Daigle K; Jones HE; Nielsen DA
Genes Brain Behav; 2018 Sep; 17(7):e12476. PubMed ID: 29575474
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic variation in the mu-opioid receptor gene in infants with neonatal abstinence syndrome.
Wachman EM; Hayes MJ; Lester BM; Terrin N; Brown MS; Nielsen DA; Davis JM
J Pediatr; 2014 Sep; 165(3):472-8. PubMed ID: 24996986
[TBL] [Abstract][Full Text] [Related]
4. Variations in opioid receptor genes in neonatal abstinence syndrome.
Wachman EM; Hayes MJ; Sherva R; Brown MS; Davis JM; Farrer LA; Nielsen DA
Drug Alcohol Depend; 2015 Oct; 155():253-9. PubMed ID: 26233486
[TBL] [Abstract][Full Text] [Related]
5. Association of OPRM1 and COMT single-nucleotide polymorphisms with hospital length of stay and treatment of neonatal abstinence syndrome.
Wachman EM; Hayes MJ; Brown MS; Paul J; Harvey-Wilkes K; Terrin N; Huggins GS; Aranda JV; Davis JM
JAMA; 2013 May; 309(17):1821-7. PubMed ID: 23632726
[TBL] [Abstract][Full Text] [Related]
6. Association of maternal and infant variants in PNOC and COMT genes with neonatal abstinence syndrome severity.
Wachman EM; Hayes MJ; Sherva R; Brown MS; Shrestha H; Logan BA; Heller NA; Nielsen DA; Farrer LA
Am J Addict; 2017 Jan; 26(1):42-49. PubMed ID: 27983768
[TBL] [Abstract][Full Text] [Related]
7. Reconceptualizing non-pharmacologic approaches to Neonatal Abstinence Syndrome (NAS) and Neonatal Opioid Withdrawal Syndrome (NOWS): A theoretical and evidence-based approach.
Velez ML; Jordan CJ; Jansson LM
Neurotoxicol Teratol; 2021; 88():107020. PubMed ID: 34419619
[TBL] [Abstract][Full Text] [Related]
8. Reconceptualizing non-pharmacologic approaches to Neonatal Abstinence Syndrome (NAS) and Neonatal Opioid Withdrawal Syndrome (NOWS): A theoretical and evidence-based approach. Part II: The clinical application of nonpharmacologic care for NAS/NOWS.
Velez ML; Jordan C; Jansson LM
Neurotoxicol Teratol; 2021; 88():107032. PubMed ID: 34600100
[TBL] [Abstract][Full Text] [Related]
9. Variations in Infant CYP2B6 Genotype Associated with the Need for Pharmacological Treatment for Neonatal Abstinence Syndrome in Infants of Methadone-Maintained Opioid-Dependent Mothers.
Mactier H; McLaughlin P; Gillis C; Osselton MD
Am J Perinatol; 2017 Jul; 34(9):918-921. PubMed ID: 28320034
[No Abstract] [Full Text] [Related]
10. Beyond the Finnegan scoring system: Novel assessment and diagnostic techniques for the opioid-exposed infant.
Schiff DM; Grossman MR
Semin Fetal Neonatal Med; 2019 Apr; 24(2):115-120. PubMed ID: 30738754
[TBL] [Abstract][Full Text] [Related]
11. A case-control study comparing rates and diagnoses of hospital readmission in infants affected by neonatal abstinence syndrome.
Salt E; Wiggins A; Pick A; Bada H; Howard C; Currie M; Rayens MK
J Matern Fetal Neonatal Med; 2023 Dec; 36(1):2162820. PubMed ID: 36597833
[TBL] [Abstract][Full Text] [Related]
12. Neonatal Abstinence Syndrome in West Virginia Substate Regions, 2007-2013.
Stabler ME; Long DL; Chertok IR; Giacobbi PR; Pilkerton C; Lander LR
J Rural Health; 2017 Jan; 33(1):92-101. PubMed ID: 26879950
[TBL] [Abstract][Full Text] [Related]
13. Models of care for neonatal abstinence syndrome: What works?
Whalen BL; Holmes AV; Blythe S
Semin Fetal Neonatal Med; 2019 Apr; 24(2):121-132. PubMed ID: 30926259
[TBL] [Abstract][Full Text] [Related]
14. Neonatal Abstinence Syndrome Management: A Review of Recent Evidence.
Grossman M; Seashore C; Holmes AV
Rev Recent Clin Trials; 2017; 12(4):226-232. PubMed ID: 28814260
[TBL] [Abstract][Full Text] [Related]
15. Trends of Neonatal Abstinence Syndrome Epidemic and Maternal Risk Factors in Florida.
Wang X; Zhu Y; Dave CV; Alrwisan AA; Voils SA; Winterstein AG
Pharmacotherapy; 2017 Jul; 37(7):806-813. PubMed ID: 28500694
[TBL] [Abstract][Full Text] [Related]
16. Neonatal abstinence syndrome: Pharmacologic strategies for the mother and infant.
Kraft WK; Stover MW; Davis JM
Semin Perinatol; 2016 Apr; 40(3):203-12. PubMed ID: 26791055
[TBL] [Abstract][Full Text] [Related]
17. Early Prediction Tool to Identify the Need for Pharmacotherapy in Infants at Risk of Neonatal Abstinence Syndrome.
Isemann BT; Stoeckle EC; Taleghani AA; Mueller EW
Pharmacotherapy; 2017 Jul; 37(7):840-848. PubMed ID: 28500629
[TBL] [Abstract][Full Text] [Related]
18. Impact of psychiatric medication co-exposure on Neonatal Abstinence Syndrome severity.
Wachman EM; Warden AH; Thomas Z; Thomas-Lewis JA; Shrestha H; Nikita FNU; Shaw D; Saia K; Schiff DM
Drug Alcohol Depend; 2018 Nov; 192():45-50. PubMed ID: 30205307
[TBL] [Abstract][Full Text] [Related]
19. Opioid neonatal abstinence syndrome: controversies and implications for practice.
Wolff K; Perez-Montejano R
Curr Drug Abuse Rev; 2014; 7(1):44-58. PubMed ID: 25323126
[TBL] [Abstract][Full Text] [Related]
20. Long-Term Outcomes of Infants with Neonatal Abstinence Syndrome.
Maguire DJ; Taylor S; Armstrong K; Shaffer-Hudkins E; Germain AM; Brooks SS; Cline GJ; Clark L
Neonatal Netw; 2016; 35(5):277-86. PubMed ID: 27636691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
